Genzyme Tissue Repair (GZTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Knighty Tin who wrote (2529)	3/7/2000 8:09:00 PM
From: Greg Jung	Read Replies (1) of 2553

Does BXM price make sense, or is there an unexploited arbitrage there. BXM shares in deal get $37 cash or 1 share of new company. Downgrades were made (The one analyst that wouldn't revise upwards their target) and stock dropped, ok but you can sell a May 35 put for $6, etc. and BXM is at $30. The price acts like it is simply a cash buyout - I don't understand. It doesn't look rational. You can buy BXM and try it out for a guaranteed 20% return or 1 share in a new biotech development company that might give you much better returns. Conference calls: gztr Wed a.m., gzsp later in week.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next